Treatment considerations in node-positive prostate cancer

“We showed that genetic correction of PSA levels has the potential to both reduce unnecessary biopsies and improve our ability to detect tumors with a more aggressive profile," says Linda Kachuri, PhD, MPH.

Amar Kishan, MD, highlights findings showing that MRI-guided SBRT is superior to CT-guided SBRT in localized prostate cancer.

The phase 3 PROpel trial provided the primary supporting data for the approval.

“Localized prostate cancer is a very complicated disease space,” says Aaron A. Laviana, MD, MBA.

Increasing numbers of older patients with cancer necessitates adoption of an age-friendly approach to cancer care.

“These results validate the clinical value of bone biomarker assessment in the HSPC state," state the authors.